Literature DB >> 7585212

Immunomodulation to enhance gene therapy.

C Wilson1, M A Kay.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7585212     DOI： 10.1038/nm0995-887

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  6 in total

1.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.

Authors:  K B Elkon; C C Liu; J G Gall; J Trevejo; M W Marino; K A Abrahamsen; X Song; J L Zhou; L J Old; R G Crystal; E Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma.

Authors:  M E Rosenfeld; M Wang; G P Siegal; R D Alvarez; G Mikheeva; V Krasnykh; D T Curiel
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

Review 3.  Strategies for cancer gene therapy using adenoviral vectors.

Authors:  V Descamps; M T Duffour; M C Mathieu; N Fernandez; L Cordier; M A Abina; E Kremer; M Perricaudet; H Haddada
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

4.  Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung.

Authors:  Y Peng; J Trevejo; J Zhou; M W Marino; R G Crystal; E Falck-Pedersen; K B Elkon
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors.

Authors:  A I Michou; H Lehrmann; M Saltik; M Cotten
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration.

Authors:  C B Wilson; L J Embree; D Schowalter; R Albert; A Aruffo; D Hollenbaugh; P Linsley; M A Kay
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.